China approves three Gilead remdesivir patents for COVID-19 treatment

27-02-2020

Edward Pearcey

China approves three Gilead remdesivir patents for COVID-19 treatment

Sundry Photography / Shutterstock.com

US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration (CNIPA).


China, remdesivir, Gilead, patents, COVID-19, He Zhimin, National Intellectual Property Administration, CNIPA, clinical trials

LSIPR